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Overview
• Key Objectives
– Difficulties surrounding the diagnosis
• What is Growth Hormone Deficiency
• Case Study
• Growth hormone therapy in UK
• Specialist clinics at Great Ormond Street 
Hospital
• Transition
Growth Hormone Deficiency
• Many reasons why a child may present with short stature
• Most common reason why a child presents with short 
stature:
– Constitutional delay of growth and puberty
– Idiopathic short stature
– Genetic short stature
• Important reason:
– Growth hormone deficiency (GHD)
– 1- 4000 children
Short Stature
• Genetic
• Pubertal and growth 
delay
• SGA 
• Dysmorphic syndromes
– Noonan
– Prader Willi
– Turner
– Laron
• SHOX deficiency
• Growth Hormone 
Deficiency (GHD)
• Hypothyroidism
• Cushing’s syndrome
• GH Resistance
• Chronic paediatric 
diseases
• Psychosocial 
deprivation
Causes of GHD
• Due to the pituitary 
gland not being able to 
produce enough GH to 
facilitate the growth 
process
Diagnosis
Growth Hormone Stimulation Tests
Diagnosis
• Glucagon Stimulation 
Test
• Confirmed by a peak GH 
level below 20mU/L (7 
ng/ml)
– Short stature
– Slow growth
– Delayed bone age
International Consensus
• Growth Hormone testing
– Glucagon
– Insulin Tolerance Test
– Arginine
– Clonidine
– Other…
Quick quiz 1
• What is NOT true about growth hormone 
deficiency?
– A
• A head injury could cause GHD
– B
• 15mcg/kg of Glucagon is given IM during a Glucagon 
stimulation test
– C
• The GH peak on testing should be above 7ng/ml
– D
• The incidence is approximately 1- 4000 children
Answer - C
• The peak on GH testing should be BELOW 
7ng / ml 
– Department of Health NICE Guidelines
• International Consensus..?
Case Presentation
Tom is a 5 year old boy presenting 
with short stature
Presented to hospital when 3
History
• Male
• Born in 2004
• White British
• No consanguinuity
• Birth weight: 3.49kg
• Gestation: Term + 6
• Parents height
– Mother: 168.6cm
– Father: 178.0cm
31
BRCA2+
6m3
Past Medical History
• Tom was diagnosed with a Leptomeningeal
low grade glioma in 2008 when he was 3 years 
old
– Tumour was in the posterior fossa region
• Growth data during oncology treatment
– Fell down the centiles
Post Fossa Tumours
• Cerebellum
– Controls the movement of 
voluntary muscles, balance, 
posture and in co-ordinating 
movements
• Brainstem
– Co-ordinates functions such 
as breathing, BP, HR
– Contains Reticular Formation 
– responsible for 
consciousness, drowsiness 
and attention
Low Grade Glioma
• Benign tumours
– Brain cells –
• Astrocytes
• Can arise anywhere in the brain or spinal cord
• Treatment
– Surgery
– Radiotherapy – older children
– Chemotherapy
• Potential late effects
– Growth, hormonal
– Behavioural changes
• Learning problems
• Difficulties with co-ordination
– Hearing and visual disturbances
Past medical history
• Family history of breast cancer
– Mother – BRCA2 positive – screening programme 
started
• Tom treated with:
– Surgery
• VP Shunt
– Low grade glioma chemotherapy protocol
– Completed October 2009 when Tom was 5
• Vincristine
• Carboplatin
Presentation to Neuro-Oncology-
Endocrine Clinic
• June 2009 – Tom is nearly 5
• Hypertension
– Hydralazine
– Nifedipine
• Ophthalmology normal
• Neurology – under assessment
– Seizures
– Neuropathy
• Residual disease still present
• ‘Growth arrest’ since starting chemotherapy over the 
last year
• No direct endocrine intervention needed currently, but 
to review growth velocity and any pubertal progress  
Subsequent clinic visits
• October 2009 (5yrs)
– Prepubertal
• April 2010 (5.5yrs)
– Has completed 
chemotherapy
– Hearing deficit
– Renal tubal toxicity
– Physiotherapy and 
occupational therapy
– Goes to nursery
• October 2012 (8yrs)
– Borderline 3rd centile on 
most scores on 
neurocognitive 
assessment
– Challenging behaviour
• Mum blames on early 
puberty, but no physical 
evidence
– ‘Not growing as well as 
he should’
– Referral for Glucagon, 
TRH and LHRH test
Clinical Investigations
Previous baseline investigations
Name of Test Range 08.10.09 18.11.10
FT4 pmol/L 10.8 - 19.0 16.3 13.8
TSH mU/L <6 2.9 2.7
Prolactin mU/L 59 – 271 109 163
Cortisol nmol/l 579 425
LH IU/L 0.7 – 6.5 0.3 <0.2
FSH IU/L 0.1 – 5.8 1.2 <0.2
Testosterone nmol/L <0.69 <0.69
IGF-1ng/ml 52 – 297 47 64
IGF-BP3mg/L 1.3 – 5.6 1.80 2.66
Pituitary Function tests
February 2013 (8.3yrs)
Glucagon Test: 15mcg/kg (0.43mg) IM
T = - 30 0 30 60 90 120 150 180
Glucose (mmol/L) 4.7 4.6 6.5 5.7 4.4 4.0 4.1 4.2
Growth Hormone
(μg/L)
0.2 0.4 1.9 0.7 1.6 4.2 1.6 0.4
Cortisol
(nmol/L)
268 469 508 659 582
(Min)
Pituitary Function tests – 8.3yrs
LHRH test
– Pubertal response?
TRH test
- Normal response
Pubertal Staging: 1 1 1 02 02
T= 0 20 60
LH (IU/L) 0.7 6.8 5.5
FSH (IU/L) 1.7 3.4 3.8
T= 0 20 60 Ref range
FT4 (pmol/L) 10.2 12-22
TSH (mU/L) 1.3 12 9.8 <6.0
Difficulties surrounding the diagnosis
• Puberty interfering?
• Long follow-up to ascertain GHD
• Continued follow-up in multi clinics
– Accurate auxology?
– DNA to any clinics
Treatment
• Decision to start GH 
February 2013
– 0.4mg daily s/c
• 0.025mcg/kg/day
• Zomajet Vision X
– Ferring
• Needle free device
– Transjection
• 10 mg, 4 mg vials
• Fridge
• Reconstitution
Response to Treatment – June 2014 –
9.65yrs
• Good response
– ? Early puberty
• G2
• P2
• A1
• TV 4
– GnRH analogue 
commenced Nov 2013
• Decapeptyl 11.25mg every 
10 weeks 
• GH dose increased to 
0.8mg daily
– Further follow up at the 
end of this year
Summary
• Complex child with obvious need for follow up 
in a neuro-oncology endocrine clinic
• Regular strict follow-up enabled early 
diagnosis of GHD 
• Good prognosis for catch-up growth, along 
with regression / halting early puberty with 
GnRH analogue
Growth Hormone Therapy in the UK
• Decision to prescribe GH made by hospital Consultant
• Liaise with GP / homecare companies / local funsing
authorities
• Prescribe in line with NICE guidelines
• Patient choice of GH device
– 12 devices
• 6 licensed indications for GH in the UK
• Continue until end of linear growth or HV <2cm/yr
– Transition
GH paediatric licensed indications - dosing
• GHD
– 0.025mg – 0.05mg / kg / day
• TS
– 0.045mg / kg / day
• SGA
– 0.035mg / kg / day
• CRI
– 0.05mg / kg / day
• PWS
– 0.035mg / kg / day
• SHOX deficiency
– 0.045 – 0.05mg / kg / day
GH devices
Quick quiz 2
• What is NOT a licensed indication for GH in 
the UK?
– A
• Turner Syndrome
– B
• Idiopathic Short Stature
– C
• Chronic Renal Failure
– D
• SHOX deficiency
Answer - B
• Idiopathic short stature not a licensed 
indication for growth hormone therapy in the 
UK
– UK NICE GUIDELINES
• GHD
• TS
• PWS
• CRI
• SHOX
• SGA
Specialist clinics – growth hormone
• Neuro-Oncology Endocrine
• Septo-Optic Dysplasia
• Turner Syndrome
– Congenital Hypothyroidism
– Adrenal
– DSD
– Thyroid surgery
– General endocrinology
Neuro-Oncology-Endocrine
• ‘Late Effects’
– Meet early on in oncology journey
• Chemotherapy
• Radiotherapy
• Long term steroid treatment
• Growth
• Puberty
• Ophthalmology
• Neurology
• Audiology
• School
– Neurocognition
Growth hormone treatment: 
‘Late Effects’
• Particularly susceptible if received craniospinal
irradiation
• 85% of cancer survivors
– Young
– Intensive treatment 
– CNS tumours
• Cognitive
• Neuropsychological 
• Endocrine impairment
• Evidence that chemotherapy alone can affect growth 
and puberty
• Commence GH when active disease still present?
Tom’s treatment
• Surgery
• Chemotherapy
– Vincristine
• Peripheral neuropathy
– Carboplatin
• Auditory dysfunction
• Renal dysfunction
Hypothalamic pituitary axis can be affected even in 
the absence of radiotherapy
Quick quiz 3
• How long do you think children who have had a 
brain tumour should be followed within 
endocrinology?
– A
• During their oncology treatment  only
– B
• From diagnosis until transition
– C
• When they have reached puberty
– D
• Until they have stopped growth hormone treatment
Answer - B
• Theoretically from diagnosis until they are 
discharged from paediatrics and into adult 
services and ?long-term rehab
– Neurology
– Gynaecology
– Endocrinology
• Long term monitoring of growth and puberty
– Other hormone deficiencies
• Transition
Transition - ESPE Guidance
• 2004 Consensus 
guidelines
– Re- evaluating the need 
for GH treatment
– Re-evaluation of GH 
and IGF-1 at end of 
linear growth
Quick quiz 4
• How long should the transition process take?
– A
• 5 minute chat just before child turns 18
– B
• When the child has finished taking GH
– C
• As soon as the child turns 13
– D
• At least 3 years 
Answer - D
• Transition discussions
– Put to child and family early
– Discuss long term goals
– Introduce adolescent teams / adult physicians
Conclusion
• Children treated with brain tumours
– Intense follow up – diagnose GHD early
• Advise intense CNS input
– Good rapport with child and family
– Build confidence
– Encourage compliance
• Good response to GH
• Discuss transition
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